1. Generics Bulletin
  2. >>Products
  3. >>Generics

Jonathan Kimball Named IGBA Chair For 2023

IGBA Also Announces Round Of Other Appointments

 
• By Rosalind Rei

The IGBA chair passes to Jonathan Kimball. He will head the global off-patent industry organization as it steps up its activities in global policy.

World map made up of white pills
Kimball takes over as IGBA Chair as the organization steps up industry advocacy on global policy • Source: Shutterstock

Jonathan Kimball will be the 2023 chair of the International Generic and Biosimilar Medicines Association, the IGBA has announced.

More from Generics

More from Products

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

 
• By Dean Rudge

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

Another One Bites The Dust: FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

 
• By Urtė Fultinavičiūtė

The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?

Teva Provigil ‘Pay For Delay’ Fines Should Stand, AG Says

 
• By Dave Wallace

Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.